EUVIMEDEUVIMED entdecken
Open Access

Metformin Ameliorates Diabetes‐Associated Cognitive Dysfunction via p53/Parkin‐Mediated Mitophagy

Wangjun Xu, Lulu Di, Xian Wang, Qinghe Miao, Jingwei Sun, Ran Zhao, Xinmei Xie, Yangyang He, Xi Li, Yunfeng Zhou iD, Lida Du, Xiaobin Pang

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.71093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Wangjun Xu und 11 weiteren Autor:innen. Beteiligte Einrichtung: The Zhongzhou Laboratory for Integrative Biology, School of Pharmacy, Henan University, Kaifeng, China. Hauptthemen laut MEDLINE: Metformin, Mitophagy, Tumor Suppressor Protein p53, Ubiquitin-Protein Ligases. Die Arbeit nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: The National Natural Science Foundation of China, The Training Program for Young Backbone Teachers in Higher Education Institutions of Henan Province, The Youth Promotion Project of Zhongzhou Laboratory for Integrative Biology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diabetes‐associated cognitive dysfunction (DACD) is a common and serious diabetic complication, and emerging evidence has identified impaired mitophagy as its potential pathological feature. Metformin (Met) possesses both hypoglycemic and cognitive‐enhancing activities, and also exerts modulatory effects on mitophagy. However, the precise mechanisms by which it regulates mitophagy to ameliorate DACD remain poorly understood.

Aims

Our present study aims to verify the ameliorative effects of Met on cognitive dysfunction in DACD mice, and to explore its underlying mechanisms. Materials and Methods Cognitive function of type 2 diabetes mellitus (T2DM) mice was evaluated by behavioural tests after Met administration. Proteomic profiling and multiple molecular biology techniques were utilised to explore and validate the effect of Met on mitophagy in T2DM mice, as well as in high glucose (HG)‐injured HT22 and SH‐SY5Y cells.

Results

We found that Met significantly alleviated cognitive impairment and neuronal damage in T2DM mice. Proteomic analysis indicated that the effect of Met in improving cognition might be closely related to mitophagy regulation. Furthermore, Met markedly downregulated Beclin1, Atg4, Atg7, LC3 II, PINK1, and Parkin in the hippocampus of T2DM mice, while upregulating p62 levels. Simultaneously, Met reduced the colocalisation of mitochondria and autophagosome marker LC3B, and the colocalisation of mitochondria and lysosome. These results indicated that Met could reverse excessive mitophagy activation. Moreover, Met dramatically increased the cytoplasmic expression of p53 and Parkin, while inhibiting the translocation of Parkin to damaged mitochondria. Consistent results were also observed in HG‐injured HT22 and SH‐SY5Y cells after Met incubation. Notably, the effect of Met on mitophagy and p53 was blocked by the p53 inhibitor PFT‐α.

Discussion

Our study confirmed that Met inhibited the mitochondrial localisation of Parkin by elevating cytosolic p53 levels, thereby preventing excessive mitophagy and ameliorating DACD.

Conclusion

These findings indicated that Met might have potential for clinical repurposing in the treatment of DACD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminMitophagyTumor Suppressor Protein p53Ubiquitin-Protein LigasesCognitive DysfunctionDiabetes Mellitus, Type 2Hypoglycemic AgentsAnimalsMiceMaleHumansHippocampusMice, Inbred C57BLDiabetes Mellitus, ExperimentalMitochondria

Stichwörter der Autor:innen

diabetes‐associated cognitive dysfunctionmetforminmitophagyp53/Parkin pathway

Substanzen

MetforminTumor Suppressor Protein p53Ubiquitin-Protein Ligasesparkin proteinHypoglycemic AgentsTrp53 protein, mouse

Autor:innen und Institutionen

  • The Zhongzhou Laboratory for Integrative Biology, School of Pharmacy, Henan University, Kaifeng, China.
  • Institute of Molecular Medicine & Innovative Pharmaceutics, Qingdao University, Qingdao, China.
  • State Key Laboratory of Antiviral Drugs, School of Pharmacy, Henan University, Kaifeng, China.
  • Department of Anesthesiology, Huaihe Hospital of Henan University, Kaifeng, Henan, China.
  • Henan Key Laboratory of Cardiac Electrophysiology, PEVI Instruments Co., Ltd, Henan, China.

ORCID-Profile: Yunfeng Zhou

Förderung

  • The National Natural Science Foundation of China
  • The Training Program for Young Backbone Teachers in Higher Education Institutions of Henan Province
  • The Youth Promotion Project of Zhongzhou Laboratory for Integrative Biology
  • The Natural Science Foundation of Henan
  • The Key R&D Program of Henan Province
  • Academic Projects of Henan Association for Science and Technology
  • Key Scientific Research Projects of Henan Higher Education Institutions

Zitieren

APA

Xu, W., Di, L., Wang, X., Miao, Q., Sun, J., Zhao, R., Xie, X., He, Y., Li, X., Zhou, Y., Du, L., & Pang, X. (2026). Metformin Ameliorates Diabetes‐Associated Cognitive Dysfunction via p53/Parkin‐Mediated Mitophagy. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71093

Vancouver

Xu W, Di L, Wang X, Miao Q, Sun J, Zhao R, et al. Metformin Ameliorates Diabetes‐Associated Cognitive Dysfunction via p53/Parkin‐Mediated Mitophagy. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71093

BibTeX
@article{Xu2026,
  author = {Xu, Wangjun and Di, Lulu and Wang, Xian and Miao, Qinghe and Sun, Jingwei and Zhao, Ran and Xie, Xinmei and He, Yangyang and Li, Xi and Zhou, Yunfeng and Du, Lida and Pang, Xiaobin},
  title = {Metformin Ameliorates Diabetes‐Associated Cognitive Dysfunction via p53/Parkin‐Mediated Mitophagy},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71093}
}
Kostenlos starten →